New stroke drug shows promise in Mid-Stage trial

NCT ID NCT05686642

Recruiting now Disease control Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests a drug called LT3001 in 300 people who have had an acute ischemic stroke. Participants receive either a high or low dose of LT3001 or a placebo by IV infusion within 24 hours of their stroke. The study aims to see if the drug is safe and helps improve recovery, measured by disability scores and stroke severity scales.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LT3001 (a drug given by IV infusion)
What this could lead to: If successful, this could lead to a new treatment option for acute ischemic stroke that improves recovery and reduces disability.
What could go wrong: This is an early Phase II trial with 300 participants, so results may not confirm benefit. The drug could have side effects or fail to improve outcomes compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Show contact details

Locations

Beijing Luhe Hospital Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 101199, China

Contact Email: •••••@•••••
Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, 100070, China
Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, 102218, China
Beipiao Central Hospital
RECRUITING

Chaoyang, Liaoning, 122199, China
Central People's Hospital of Zhanjiang
RECRUITING

Zhanjiang, China
Daqing Oilfield General Hospital
RECRUITING

Daqing, Heilongjiang, 163001, China
Harrison International Peace Hospital
RECRUITING

Hengshui, Hebei, 053099, China
Huai'an Second People's Hospital
RECRUITING

Huai'an, Jiangsu, 223022, China
Inner Mongolia Baogang Hospital
RECRUITING

Baotou, Inner Mongolia, 750306, China
Liaocheng People's Hospital
RECRUITING

Liaocheng, Shandong, 252004, China
Linfen Central Hospital
RECRUITING

Linfen, China
Linfen People's Hospital
RECRUITING

Linfen, China
Luoyang Third People's Hospital
RECRUITING

Luoyang, He'nan, 471002, China
Nanshi Hospital of Nanyang
RECRUITING

Nanyang, China
Pingxiang People's Hospital
RECRUITING

Pingxiang, Jiangxi, 337000, China
Shanghai Pudong Hospital
RECRUITING

Shanghai, 201399, China
Taizhou First People's Hospital
RECRUITING

Taizhou, Zhejiang, 318020, China
Taizhou Municipal Hospital
RECRUITING

Taizhou, Zhejiang, 318000, China
The Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, Jiangsu, 221000, China
The First Affiliated Hospital of Baotou Medical College
RECRUITING

Baotou, Inner Mongolia, 014017, China
The First Affiliated Hospital of Jinan University
RECRUITING

Guangzhou, Guangdong, 510630, China
The First Bethune Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130061, China
The Second Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215004, China
The Third Hospital of Mianyang
RECRUITING

Mianyang, Sichuan, China
Xi'an Gaoxin Hospital
RECRUITING

Xi’an, Shanxi, 710077, China
Yan'an University Xianyang Hospital
RECRUITING

Xianyang, Shanxi, 716099, China
Zhejiang Hospital
RECRUITING

Hangzhou, Zhejiang, 310013, China
Zhongnan Hospital of Wuhan University
RECRUITING

Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.